If only 25% of adults are
vaccinated against pertussis1,
where does that leave
the other 75%?

Despite ACIPa, CDCb, and AAFPc guidelines for Tdapd vaccine,2,3 only 1 in 4 adults received a Tdap vaccine.1

“Persons aged ≥ 19 years who previously have not received a dose of Tdap should receive a single dose of Tdap in place of decennial Tde booster dose.” - ACIP, 20182

  • Adacel vaccine is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) to any other tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine, or to any component of Adacel; or encephalopathy within 7 days after a previous dose of a pertussis antigen-containing vaccine with no other identifiable cause4
  • After the first and second dose of AdaceI, the most frequently reported solicited reactions were pain, swelling, and erythema at the injection site; headache, body ache or muscle weakness, tiredness, myalgia, and malaise4

a ACIP = Advisory Committee on Immunization Practices.

b CDC = Centers for Disease Control and Prevention.

c AAFP = American Academy of Family Physicians.

d Tdap = Tetanus, diphtheria, and acellular pertussis.

e Td = Tetanus and diphtheria.

The first and only Tdap vaccine to be approved for repeat vaccination and made without natural rubber latex4

  • Pertussis protection acquired from vaccination can wane, leaving patients at risk2
  • Adacel vaccine can be administered as a booster 8 years or more after the initial Tdap vaccination4
  • For wound management, Adacel can be given as early as 5 years after a previous dose of Tdap or other tetanus toxoid-containing vaccine4

initial initialmob
booster boostermob
wound woundmob

Currently, an estimated 14 million people in the US may have a sensitivity to natural rubber latex5,6

  • Using a vaccine available in a prefilled syringe not made with natural rubber latex in your practice may help reduce risk of anaphylaxis for your patients who have a history of severe allergy to latex7

Over 150 Million doses distributed over a decade8

fDTaP = Diphtheria, tetanus toxoids, and acellular pertussis.

When eligible patients come in for
influenza vaccination, also think
Tdap vaccination

Adacel vaccine can be given concomitantly with influenza vaccine4

Help protect your patients as young as 10 years old4

  • Adacel is approved for use in individuals 10 through 64 years of age4
  • Immunize your adolescent patients as early as the fifth or sixth grade4
  • Immunize your patients with Tdap again before they age out of the practice
  • Adacel vaccine is available through the VFCg program

g VFC = Vaccines for Children Program.

INDICATION FOR ADACEL VACCINE

Adacel vaccine is indicated for active booster immunization against tetanus, diphtheria, and pertussis. Adacel is approved for use in individuals 10 through 64 years of age.

IMPORTANT SAFETY INFORMATION
FOR ADACEL VACCINE

Adacel vaccine is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) to any other tetanus toxoid‐, diphtheria toxoid‐, or pertussis antigen‐containing vaccine, or to any component of Adacel; or encephalopathy within 7 days after a previous dose of a pertussis antigen‐containing vaccine with no other identifiable cause.

For one presentation of Adacel, the tip caps of the prefilled syringes may contain natural rubber latex, which may cause allergic reactions in latex‐sensitive individuals. The vial stopper is not made with natural rubber latex.

If Guillain‐Barré syndrome or brachial neuritis has occurred within 6 weeks following previous vaccination with a tetanus toxoid‐containing vaccine, if progressive or unstable neurologic disorders exist, or if adverse events have occurred in temporal relation to receipt of pertussis antigen‐containing vaccine, the decision to give Adacel should be based on careful consideration of the potential benefits and risks.

Persons who experienced an Arthus‐type hypersensitivity reaction following a prior dose of tetanus toxoid‐containing vaccine should not receive Adacel unless at least 10 years have elapsed since the last dose of tetanus toxoid‐containing vaccine.

Syncope (fainting) can occur in association with administration of injectable vaccines, including Adacel. Procedures should be in place to prevent falling injury and manage syncopal reactions.

After the first and second dose of Adacel, the most frequently reported solicited reactions were pain, swelling, and erythema at the injection site; headache, body ache or muscle weakness, tiredness, myalgia, and malaise.

Other adverse reactions may occur. Vaccination with Adacel may not protect all individuals.

References: 1. Centers for Disease Control (CDC). Surveillance of Vaccination Coverage Among Adult Populations, United States, 2015. MMWR. 2017;66(11):1-32. 2. Liang JL, Tiwari T, Moro P, et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2018;67(2):1-48. 3. American Academy of Family Physicians (AAFP). Adult immunization schedule. https://www.aafp.org/patient-care/public health/immunizations/schedules/adult-schedule.html. Updated February 7, 2018. Accessed June 25, 2019. 4. Adacel vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc. 5. Wu M, McIntosh J, Liu J. Current prevalence rate of latex allergy: why it remains a problem? J Occup Health. 2016;58(2):138-144. 6. US Census Bureau. US and world population clock. https://www.census.gov/popclock/. Updated January 18, 2019. Accessed August 27, 2019. 7. Kroger A, Atkinson W, Pickering L. General immunization practices. In Plotkin S, Orenstein W, Offit P, eds. Vaccines. 6th ed. China. Elsevier Saunders, 2013:88-111. 8. Sanofi Pasteur Inc. Data on File (2019).

*

Back to the top ▲

© 2019 Sanofi Pasteur Inc.

Legal Disclaimer | Privacy Policy | Contact Us

This site is intended for use by US Healthcare Professionals only.

SAUS.ADAC.19.07.4074 Last Updated: 12/19

IMPORTANT SAFETY INFORMATION
FOR ADACEL VACCINE

Adacel vaccine is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) to any other tetanus toxoid‐, diphtheria toxoid‐, or pertussis antigen‐containing vaccine, or to any component of Adacel; or encephalopathy within 7 days after a previous dose of a pertussis antigen‐containing vaccine with no other identifiable cause.